Overview
Investment Type
Venture Capital
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 8, 2025 | Integra Therapeutics raises €10.7M to advance FiCAT platform and CAR-T validation | Barcelona-based Integra Therapeutics has closed a €10.7 million pre-Series A round to advance its gene writing technologies designed to improve the safety, precision, and efficacy of advanced therapies. Founded in 2020 by Dr. Marc Güell and... |
| Mar 19, 2025 | Egle Therapeutics Secures €9.3 Million to Advance Immuno-Oncology Research | Egle Therapeutics is on the rise. The Paris-based biotechnology company has just secured €9.3 million in state funding. This investment comes from the French government’s France 2030 initiative, specifically under the “Innovations in Biothe... |
| Mar 18, 2025 | Egle Therapeutics: €9.3 Million In State Funding Raised To Develop Therapies Targeting Regulatory T Cells | Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, announced that it secured €9.3 million in state funding under the Innovations i... |
| Dec 2, 2021 | Integra Tx cierra una ronda de €4,5M a la que han acudido Advent France Biotechnology, Invivo Capital y Takeda Ventures | 02/12/2021 Nota de prensa INTEGRA TX CIERRA UNA RONDA DE €4,5M CON ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL Y TAKEDA VENTURES. La biotecnológica, especializada en edición genética y fundada por los investigadores Marc Güell y Avencia ... |
| Dec 2, 2021 | Integra Tx secures €4.5M in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures | 02/12/2021 Press release INTEGRA TX SECURES €4.5 MILLION IN FUNDING FROM ADVENT FRANCE BIOTECHNOLOGY, INVIVO CAPITAL AND TAKEDA VENTURES. The biotechnology company, which specialises in gene editing and was founded by researchers Marc Gü... |
| Oct 22, 2021 | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers About Egle Therapeutics About LSP About Bpifrance – InnoBio 2 About Takeda Ventures Inc. About Fund+ About Bioqube Ventures About Institut Curie | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has c... |
| Jun 14, 2018 | StrideBio Raises $15.7M Series A | StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced today that it had closed an oversubscribed Series A Financing Round of $15.7 million. The financing was led by Hatteras Venture Partners. C... |
| May 24, 2017 | NEA Leads $39M Series A for OrphoMed | OrphoMed, Inc., a clinical stage biopharmaceutical company developing first-in-class dimer therapies, today announced the completion of a $39 million Series A financing. The round was led by New Enterprise Associates (NEA), and co-led by ex... |
| May 23, 2016 | OrbiMed launches second fund targeting Israeli biotech, health tech investments | So far it has made three investments from OrbiMed Israel Partners II in the past few months: Gene therapy company, logicBio; digital health company focused on protecting patient data in the context of medical research, MDClone; and a gene e... |
Show more
Reviews 0
FAQ about Takeda Ventures
How many startups has Takeda Ventures invested in?
Takeda Ventures has 1 portfolio company on Parsers VC.
What has the press written about Takeda Ventures?
Parsers VC has collected 14 articles mentioning Takeda Ventures, among them “Integra Therapeutics raises €10.7M to advance FiCAT platform and CAR-T validation” (Sep 8, 2025) and “Egle Therapeutics Secures €9.3 Million to Advance Immuno-Oncology Research” (Mar 19, 2025).
Is Takeda Ventures still active?
Yes, Takeda Ventures is active; its latest activity on Parsers VC dates from Oct 6, 2025.